NEJM (@nejm) 's Twitter Profile
NEJM

@nejm

The New England Journal of Medicine is the world’s leading medical journal and website.

ID: 25950355

linkhttp://NEJM.org calendar_today23-03-2009 04:10:07

34,34K Tweet

934,934K Followers

430 Following

NEJM (@nejm) 's Twitter Profile Photo
NEJM
@nejm

9 hours ago

In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results and Research Summary: nej.md/3EVFAFM

In an interim analysis of a phase 3 trial involving 800 patients with metabolic dysfunction–associated steatohepatitis, once-weekly semaglutide improved liver histologic results at 72 weeks. Full ESSENCE trial results and Research Summary: nej.md/3EVFAFM